Tech Company Financing Transactions

Syros Pharmaceuticals Funding Round

Syros Pharmaceuticals, operating out of Cambridge, secured $30 million from Arch Venture Partners, Flagship Pioneering and private investors.

Transaction Overview

Announced On
4/12/2013
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors

Arch Venture Partners (Lead Investor) (Robert Nelsen)

Flagship Pioneering (Lead Investor)

WuXi PharmaTech

Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
620 Memorial Dr. 300
Cambridge, MA 02139
USA
Email Address
Overview
Syros Pharmaceuticals (Nasdaq: SYRS) is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities.
Profile
Syros Pharmaceuticals LinkedIn Company Profile
Social Media
Syros Pharmaceuticals Company Twitter Account
Company News
Syros Pharmaceuticals News
Facebook
Syros Pharmaceuticals on Facebook
YouTube
Syros Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Nancy Simonian
  Nancy Simonian LinkedIn Profile  Nancy Simonian Twitter Account  Nancy Simonian News  Nancy Simonian on Facebook
Chief Financial Officer
Joseph Ferra
  Joseph Ferra LinkedIn Profile  Joseph Ferra Twitter Account  Joseph Ferra News  Joseph Ferra on Facebook
Chief Medical Officer
David Roth
  David Roth LinkedIn Profile  David Roth Twitter Account  David Roth News  David Roth on Facebook
Chief Scientific Officer
Eric Olson
  Eric Olson LinkedIn Profile  Eric Olson Twitter Account  Eric Olson News  Eric Olson on Facebook
VP - Bus. Development
Jeremy Springhorn
  Jeremy Springhorn LinkedIn Profile  Jeremy Springhorn Twitter Account  Jeremy Springhorn News  Jeremy Springhorn on Facebook
VP - General Counsel
Gerald Quirk
  Gerald Quirk LinkedIn Profile  Gerald Quirk Twitter Account  Gerald Quirk News  Gerald Quirk on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/12/2013: Biodesix venture capital transaction
Next: 4/15/2013: PharmaJet venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to document every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary